<DOC>
	<DOCNO>NCT00982787</DOCNO>
	<brief_summary>The purpose Phase II clinical trial see botanical extract plant Passiflora incarnata improve seizure control reduce anxiety patient diagnose partial epilepsy . The investigator randomize approximately 25 participant partial epilepsy placebo control , double blind , crossover study . All patient schedule 10 clinic visit four telephone visit 32-week period trial . After enrollment study , participant begin 9-week observation phase , serve individual baseline control . After 9 week participant randomize receive either study drug placebo 11 week study period . After completion 11 week study period , patient crossover study drug/placebo arm another 11 week . Epilepsy participant continue take anti-epileptic medication currently prescribe . The investigator find participant OHSU clinic , notify local neurologist , anthroposophical naturopathic practice , advertise study via local chapter American Epilepsy Society . Routine blood test , physical examination test monitor heart , brain muscle activity screen adverse effect . The primary outcome measure seizure frequency seizure diary . Attention performance test , neurological quality life questionnaire complete assess secondary outcome measure anxiety , cognitive function quality life .</brief_summary>
	<brief_title>Safety Anticonvulsant Efficacy Passiflora Incarnata Extract Patients With Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Age 1870 year old . Reliable history seizure semiology , EEG EEG video telemetry confirm diagnosis partial epilepsy . Seizure frequency least 6 complex partial seizure 9 week prior enrollment , 3 week period le one seizure , spite adequate treatment stable anticonvulsant dosage one two anticonvulsant least one month . Every seizure cluster count separate seizure . Willing maintain current anticonvulsant dosage 32 week . Tapering third anticonvulsant one month prior enrollment allow study participation permit . Consent obtain prior taper third anticonvulsant . Habitual use additional rescue medication lorazepam excess seizure activity permit frequently every three week . Women childbearing potential need negative urine pregnancy test practice two simultaneous method birth control , may include oral contraceptive . Due drug interaction , oral contraceptive consider safe method birth control patient use anticonvulsant medication . Women least two year postmenopausal exempt pregnancy test birth control requirement . Exclusion criterion : Unreliable history seizure semiology . Seizure frequency less six complex partial seizure 9 week seizure 3week period 9 week prior enrollment . Patients anticipated current standard care would mandate change conventional epilepsy treatment time period study exclude . Patients widely fluctuate seizure frequency ( good month bad month ) history status epilepsy exclude . Women currently pregnant lactate Patients serious medical problem , brain tumor , cancer , stroke , significant heart disease psychiatric disorder schizophrenia major depression exclude . Patients progressive epilepsy syndrome , neurodegenerative disorder dementia exclude . Patients impaired renal hepatic function detect abnormal BUN AST/ALT/alk phos initial screening exclude . Patients increase risk ventricular arrhythmia ( history heart failure , prolong QTc &gt; 450 m , family history prolong QT syndrome , hypokalemia , use diuretic drug prolong QT , see http : //www.azcert.org ) exclude . Patients high likelihood psychogenic nonepileptic seizure exclude follow method previously develop Oregon Health Science University ( OHSU ) epilepsy program . Patients use alcohol , drug participate another clinical trial past 6 month , patient find less 80 % compliant documentation seizure medication diary exclude patient unwilling stop use oral contraceptive time study enrollment . Patients agree participate currently take botanical ask discontinue enrollment , may confound study result cause safety issue . Patients find generalize spike wave discharge , diagnostic primary generalize epilepsy , EEG exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
	<keyword>Passiflora</keyword>
</DOC>